Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-27
2009-02-24
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000
Reexamination Certificate
active
07494972
ABSTRACT:
The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent accelerated atherosclerosis in the subject. The present invention also provides for a method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent macrovessel disease in the subject.
REFERENCES:
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 6555651 (2003-04-01), Stern et al.
patent: 7101838 (2006-09-01), Stern et al.
patent: WO/97/26813 (1997-07-01), None
patent: WO/97/26913 (1997-07-01), None
patent: WO/97/39121 (1997-10-01), None
patent: WO/97/39125 (1997-10-01), None
patent: WO/98/22138 (1998-05-01), None
patent: WO/99/07402 (1999-02-01), None
patent: WO/99/18987 (1999-04-01), None
patent: WO/01/12598 (2001-02-01), None
Basha et al., Atheroscl. 131: 1192-1202, 1995.
Mickle et al., Med. Clin. North Am., vol. 84(3), p. 597-607, 2000.
Adelhorst et al., J. Biol. Chem. 269: 6275-6278, 1994.
U.S. Appl. No. 09/374,214, filed Aug. 13, 1999, David Stern, et al.
U.S. Appl. No. 08/592,070, filed Jan. 26, 1996, David Stern, et al.
Brett, J., et al. “Survey of the distribution of a newly-characterized receptor for AGEs in tissues” Am. J. Pathol. 143:1699-1712 (1993).
Connolly, E.S., et al. “Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia” Neurosurg. 38:523-532 (1996).
Gibbons, G.H. and Dzau, V.J. “Molecular therapies for vascular diseases” Science 272:689-693 (1996).
Hori, et al. “The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol.” In: The Endothelium in Clinical Practice. Chapter 11, pp. 311-329 (Jan. 1997).
Khoury, J., et al. “Macrophages adhere to glucose-modified basement membrane via their scavenger receptors” J. Biol. Chem. 269:10197-10200 (1994).
Kindy, M.S. and Rader D.J. “Reduction in Amyloid A Amyloid Formation in Apolipoprotein-E-Deficient Mice” American Journal of Pathology 152:1387-1395 (1998).
Marui, N., et al. “VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells” J. Clin. Invest. 92:1866-1874 (1993).
Nakamura, Y. et al., “Immunohistochemical localization of advanced glycation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus” Am. J. Pathol. 143(6):1649-1656 (1993).
Nakashima, Y., et al. “ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree” Arteriolscler. Thromb. 141:133-140 (1994).
Palinski, W., et al. “Imunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits” Arteriolscl. Thromb. And Vasc. Biol. 15(5):571-582 (1995).
Park, L., et al. “Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)” Nature Medicine 4:1025-1031 (1998).
Park, L., et al. “A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts” Circulation Supplement. Abstract 3079 (1997).
Ritthaler, et al. “Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease” Am. J. Path. 146:688-694 (1995).
Schmidt, A.M., et al. “Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products” J. Clin. Invest. 92:2155-2168 (1993).
Schmidt, A.M., et al. “The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes” Circulation Supplement 96(194):1-37 (1997).
Schmidt, A.M., et al. “Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis” Circ. Res. 84:489-497 (1999).
Vlassara, H., et al. “Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex” Molecular Medicine 1:634-646 (1995).
Vlassara, H., et al. “Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging” Lab. Invest. 70:138-151 (1994).
Wautier, J.L., et al. “Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction” Circulation Supplement 94(8): #4139 (1996).
Yan. S.D., et al. “Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins” J. Biol. Chem. 269:9889-9897 (1994).
International Search Report issued on Nov. 4, 1998 in connection with PCT Publication No. WO/1999/007402.
Written Opinion issued on Jun. 21, 1999 in connection with PCT Publication No. WO/1999/007402.
International Preliminary Examination Report issued Nov. 30, 1999 in connection with PCT Publication No. WO/1999/007402.
Oct. 1, 1998 Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Jun. 24, 1999 Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Nov. 12, 1999 Advisory Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Jun. 15, 2000 Final Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Feb. 12, 2001 Notice of Allowance and Issue Fee Due issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Jun. 29, 2001 Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Apr. 23, 2002 Final Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Oct. 7, 2002 Advisory Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
May 7, 2003 Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Nov. 12, 2003 Final Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Mar. 9, 2004 Advisory Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Mar. 18, 2005 Office Action issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Sep. 26, 2005 Notice of Allowance issued in connection with U.S. Appl. No. 08/905,709, now U.S. Patent No. 7,101,838.
Written Opinion issued Dec. 26, 2001 in connection with PCT Publication No. WO/2001/012598.
International Preliminary Examination Report issued Apr. 19, 2002 in connection with PCT Publication No. WO/2001/012598.
International Search Report issued Jun. 22, 2001 in connection with PCT Publication No. WO/2001/012598.
Supplementary Partial European Search Report issued Feb. 21, 2005 in connection with European Patent Application No. 00955464.3, national stage of PCT Publication No. WO/2001/012598.
Communication Pursuant to Article 96(2) EPC issued May 2, 2005 in connection with European Patent Application No. 00955464.3, national stage of PCT Publication No. WO/2001/012598.
Communication Pursuant to Article 96(2) EPC issued Nov. 29, 2006 in connection with European Patent Application No. 00955464.3, national stage of PCT Publication No. WO/2001/012598.
Mar. 26, 2001 Office Action issued in connection with U.S. Appl. No. 09/374,214.
Jul. 5, 2001 Office Action issued in connection with U.S. Appl. No. 09/374,21
Schmidt Ann Marie
Stern David
Chandra Gyan
Cooper & Dunham LLP
Landsman Robert
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Method for inhibiting accelerated atherosclerosis in a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting accelerated atherosclerosis in a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting accelerated atherosclerosis in a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4140087